U2AF1L4 Antibody

What is U2AF1L4 and what is its primary function in cellular processes?

U2AF1L4 (U2 small nuclear RNA auxiliary factor 1-like 4) is an RNA-binding protein that functions as a pre-mRNA splicing factor. It plays a critical role in both constitutive and enhancer-dependent splicing by mediating protein-protein interactions and protein-RNA interactions required for accurate 3'-splice site selection. The protein acts by enhancing the binding of U2AF2 to weak pyrimidine tracts and participates in the regulation of alternative pre-mRNA splicing .

U2AF1L4 has been shown to activate exon 5 skipping of PTPRC during T-cell activation (an event reversed by GFI1) and binds to RNA specifically at the AG dinucleotide at the 3'-splice site. Notably, it shows a preference for AGC or AGA sequences, which highlights its sequence-specific binding properties in splicing regulation .

What types of U2AF1L4 antibodies are available for research applications?

Researchers can choose from several types of U2AF1L4 antibodies depending on their experimental needs:

• Based on host species:

  • Rabbit polyclonal antibodies (most common)

  • Mouse polyclonal antibodies

  • Goat polyclonal antibodies

  • Rabbit monoclonal antibodies (e.g., clone EPR14349)

• Based on clonality:

  • Polyclonal antibodies - offering broader epitope recognition

  • Monoclonal antibodies - providing higher specificity for particular epitopes

• Based on target region:

  • Full-length (AA 1-202) antibodies

  • N-terminal region-specific antibodies

  • Internal region-specific antibodies

  • C-terminal region-specific antibodies

This diversity allows researchers to select antibodies that best match their target detection requirements and experimental systems .

What are the validated applications for U2AF1L4 antibodies?

U2AF1L4 antibodies have been validated for multiple experimental applications with varying levels of optimization:

When selecting an antibody, researchers should consider which applications have been specifically validated for their target of interest and experimental system. The dilution ranges vary by application and product, typically 1:20-1:200 for IHC and 1:500-1:2000 for Western blot applications .

How should I optimize antibody dilutions for different experimental applications?

Optimization of antibody dilution is critical for achieving specific signal while minimizing background. Based on the available data:

For Western Blot applications:

• Starting dilution range: 1:500-1:2000

• Begin with manufacturer's recommended dilution and adjust based on signal-to-noise ratio

• Consider using gradient dilutions (e.g., 1:500, 1:1000, 1:2000) in preliminary experiments to determine optimal concentration

For Immunohistochemistry applications:

• Recommended dilution range: 1:20-1:200

• For paraffin-embedded tissues, a 1:100 dilution has been validated for human breast cancer and testis tissues

• Titration experiments should be performed for each new tissue type

For ELISA applications:

• Starting concentration of 1 μg/mL is recommended, with subsequent optimization based on specific assay requirements

• Consider performing a checkerboard titration to simultaneously optimize both primary antibody and detection system concentrations

Methodologically, maintain consistent incubation times and temperatures across optimization experiments, and document all parameters to ensure reproducibility .

What storage and handling practices should be followed to maintain U2AF1L4 antibody integrity?

Proper storage and handling of U2AF1L4 antibodies is essential for maintaining their activity and specificity:

• Storage temperature: Store antibodies at -20°C for long-term preservation. Most U2AF1L4 antibodies are stable for up to one year from the date of receipt under these conditions .

• Buffer composition: Most U2AF1L4 antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3. This formulation helps maintain antibody stability during freeze-thaw cycles .

• Avoiding freeze-thaw cycles: Repeated freeze-thaw cycles can degrade antibody quality. For antibodies in regular use, consider dividing the stock into smaller working aliquots .

• Working dilutions: Prepare fresh working dilutions on the day of use whenever possible.

• Safety considerations: Note that many of these antibodies contain sodium azide as a preservative, which is toxic. Appropriate handling precautions should be taken, and disposal should follow institutional guidelines .

What controls should be included when using U2AF1L4 antibodies in immunoassays?

Rigorous experimental design requires appropriate controls to validate results obtained with U2AF1L4 antibodies:

Positive controls:

• Cell lines or tissues with known U2AF1L4 expression (human breast cancer tissue and testis have been validated for some antibodies)

• Recombinant U2AF1L4 protein when available

• Lysates from cells with confirmed U2AF1L4 expression

Negative controls:

• Isotype-matched irrelevant antibody at the same concentration

• Tissues or cell lines with no or minimal U2AF1L4 expression

• Pre-adsorption control (antibody pre-incubated with immunizing peptide)

Procedural controls:

• Secondary antibody-only control to assess non-specific binding

• Blocking peptide competition assay to confirm specificity

• For IHC/ICC, include a no-primary antibody control

Validation controls:

• CRISPR/Cas9-mediated knockdown or knockout samples where possible

• siRNA-mediated knockdown of U2AF1L4

• Multiple antibodies targeting different epitopes of U2AF1L4 to confirm patterns

Including these controls helps distinguish specific from non-specific signals and validates the experimental findings, especially important given the antibody's role in detecting splicing factors that may have multiple isoforms .

How can U2AF1L4 antibodies be used to investigate splicing mechanisms?

U2AF1L4 antibodies can be powerful tools for investigating pre-mRNA splicing mechanisms through several sophisticated approaches:

Chromatin Immunoprecipitation (ChIP) assays:

• Investigate U2AF1L4 binding to pre-mRNA at specific 3' splice sites

• Combine with sequencing (ChIP-seq) to map genome-wide binding patterns

• Correlate binding patterns with specific sequence motifs (preference for AGC or AGA) to understand sequence-specific targeting

RNA Immunoprecipitation (RIP):

• Capture U2AF1L4-bound RNA complexes to identify target transcripts

• Use in conjunction with high-throughput sequencing (RIP-seq) to identify the transcriptome-wide binding profile

• Analyze the sequence context surrounding binding sites to refine understanding of the AGC/AGA preference

Co-immunoprecipitation studies:

• Identify protein interaction partners of U2AF1L4 in the spliceosome complex

• Investigate how U2AF1L4 enhances U2AF2 binding to weak pyrimidine tracts

• Study dynamics of protein complex formation during splicing regulation

Splicing reporter assays:

• Use minigene splicing reporters in conjunction with U2AF1L4 antibodies to assess the functional impact of U2AF1L4 on specific alternative splicing events

• Validate the role of U2AF1L4 in PTPRC exon 5 skipping during T-cell activation

These methodologies can be particularly valuable for investigating how U2AF1L4 contributes to both constitutive and enhancer-dependent splicing regulation, providing mechanistic insights into this critical cellular process .

What considerations are important when using U2AF1L4 antibodies for subcellular localization studies?

When using U2AF1L4 antibodies for subcellular localization studies via immunofluorescence or related techniques, researchers should consider several important factors:

Fixation and permeabilization protocols:

• Optimal fixation method: Test both paraformaldehyde (2-4%) and methanol fixation, as the epitope accessibility may differ

• Permeabilization: Triton X-100 (0.1-0.5%) is typically used, but saponin may be preferred for maintaining nuclear membrane integrity

Nuclear speckle co-localization:

• As a splicing factor, U2AF1L4 is expected to localize to nuclear speckles (splicing factor compartments)

• Co-staining with established nuclear speckle markers (e.g., SC35 or SRSF2) is recommended to confirm proper localization

• Dynamic redistribution during the cell cycle should be considered when interpreting results

Antibody selection considerations:

• Prioritize antibodies specifically validated for ICC/IF applications

• For double immunostaining, select primary antibodies from different host species to avoid cross-reactivity

• When using rabbit polyclonal antibodies, ensure they don't cross-react with other nuclear proteins

Resolution requirements:

• Consider super-resolution microscopy techniques (STED, STORM, etc.) for detailed nuclear speckle distribution

• Confocal microscopy with optical sectioning is preferred over widefield for nuclear protein localization

• Z-stack acquisition and 3D reconstruction may be necessary to fully characterize the distribution pattern

Proper attention to these technical considerations will significantly enhance the quality and interpretability of subcellular localization data for U2AF1L4, particularly given its nuclear distribution and involvement in splicing complexes .

How can U2AF1L4 antibodies be applied in studying disease-associated splicing dysregulation?

U2AF1L4 antibodies can be valuable tools for investigating splicing dysregulation in various disease contexts:

Cancer research applications:

• Immunohistochemical analysis of U2AF1L4 expression in cancer tissues (validated in breast cancer)

• Correlation of U2AF1L4 expression/localization with cancer stage, grade, and patient outcomes

• Investigation of splicing pattern alterations in tumors with aberrant U2AF1L4 expression

Immune system dysregulation:

• Study of U2AF1L4's role in PTPRC alternative splicing during T-cell activation

• Investigation of how this splicing regulation may be disrupted in autoimmune conditions

• Analysis of GFI1-mediated regulation of U2AF1L4 activity in normal versus pathological immune responses

Methodological approaches:

• Tissue microarray (TMA) analysis using optimized IHC protocols (1:100 dilution)

• Multiplex immunofluorescence to correlate U2AF1L4 with other splicing factors in disease tissues

• Quantitative Western blot to measure altered expression levels between normal and disease states

• RNA-seq combined with U2AF1L4 immunoprecipitation to identify disease-specific binding patterns

Comparative analysis framework:

• Paired normal-disease tissue analysis to establish baseline changes

• Multi-antibody approach targeting different epitopes to verify results

• Correlation with RNA-seq data to link protein expression changes with specific splicing alterations

By applying these approaches, researchers can gain insights into how alterations in U2AF1L4 function may contribute to disease pathogenesis through dysregulated splicing mechanisms .

What are common issues encountered with U2AF1L4 antibodies in Western blotting and how can they be resolved?

When using U2AF1L4 antibodies in Western blotting, researchers may encounter several challenges. Here are common issues and their solutions:

High background or non-specific bands:

• Cause: Insufficient blocking, too high antibody concentration, or cross-reactivity

• Solution: Increase blocking time (1-2 hours at room temperature with 5% non-fat milk or BSA), optimize primary antibody dilution (test 1:1000-1:2000 range), increase washing steps (4-5 washes of 5-10 minutes each)

Weak or absent signal:

• Cause: Insufficient protein loading, protein degradation, or inefficient transfer

• Solution: Increase protein load (25-50 μg per lane), add protease inhibitors during sample preparation, optimize transfer conditions (consider wet transfer for proteins <30 kDa like U2AF1L4 which is ~22 kDa)

Multiple bands or unexpected molecular weight:

• Cause: Post-translational modifications, splice variants, or degradation products

• Solution: Compare with positive control samples, use phosphatase treatment to identify phosphorylated forms, consider reducing sample heating time to minimize aggregation

• Note: U2AF1L4 has a calculated molecular weight of 22 kDa (202 amino acids) , but may appear at different positions depending on post-translational modifications

Inconsistent results between experiments:

• Cause: Variability in transfer efficiency, loading inconsistency, or antibody degradation

• Solution: Use loading controls (housekeeping proteins), include a standardized positive control in each experiment, aliquot antibodies to avoid repeated freeze-thaw cycles

Methodological optimization table:

This systematic approach to troubleshooting will help achieve reproducible and specific detection of U2AF1L4 in Western blotting applications .

How can I validate the specificity of U2AF1L4 antibodies in my experimental system?

Validating antibody specificity is critical for ensuring reliable results. For U2AF1L4 antibodies, consider these comprehensive validation approaches:

Genetic validation methods:

• CRISPR/Cas9 knockout: Generate U2AF1L4 knockout cell lines; the specific band should disappear in Western blot

• siRNA or shRNA knockdown: Perform partial knockdown and observe proportional decrease in signal intensity

• Overexpression: Create cell lines overexpressing tagged U2AF1L4 and confirm co-detection with tag-specific antibodies

Biochemical validation methods:

• Peptide competition assay: Pre-incubate antibody with immunizing peptide; specific signal should be blocked

• Multiple antibodies approach: Use antibodies targeting different epitopes of U2AF1L4 and compare detection patterns

• Immunoprecipitation-Western blot: IP with one antibody and probe with another targeting a different epitope

Species cross-reactivity assessment:

• Compare detection in human, mouse, and rat samples where reactivity has been reported

• Verify species-specific bands at the expected molecular weights (human U2AF1L4: 22 kDa)

Controls to include:

• Positive controls: Human cell lines with known U2AF1L4 expression

• Negative controls: Samples with minimal expression or knockout models

• Recombinant protein: Use purified U2AF1L4 as a standard for size verification

Documentation requirements:

• Record all validation experiments with detailed protocols

• Include appropriate controls in publication figures

• Note lot numbers as antibody performance may vary between lots

This multi-faceted validation approach ensures that observed signals genuinely represent U2AF1L4 rather than non-specific binding, thereby strengthening the reliability of your research findings .

What factors might affect immunohistochemical staining patterns with U2AF1L4 antibodies?

Several technical and biological factors can influence immunohistochemical (IHC) staining patterns when using U2AF1L4 antibodies:

Tissue preparation factors:

• Fixation method and duration: Overfixation with formalin can mask epitopes; optimize fixation time (typically 24-48h)

• Antigen retrieval method: Compare heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) versus EDTA buffer (pH 9.0) to determine optimal conditions

• Section thickness: 4-5 μm sections typically provide optimal results; thicker sections may require longer antibody incubation

Antibody-related factors:

• Epitope accessibility: Different antibodies targeting various regions of U2AF1L4 may show different staining patterns

• Antibody concentration: Validated dilutions for IHC range from 1:20 to 1:200; a 1:100 dilution has been specifically validated for human breast cancer and testis tissues

• Incubation conditions: Overnight incubation at 4°C often improves specific staining compared to 1-2 hours at room temperature

Biological variables affecting interpretation:

• Nuclear vs. cytoplasmic staining: U2AF1L4 is primarily a nuclear protein involved in splicing; predominant cytoplasmic staining should be scrutinized

• Cellular heterogeneity: Expression may vary between cell types within the same tissue

• Pathological conditions: Changes in splicing factor localization can occur in disease states

Detection system considerations:

• DAB vs. fluorescent detection: DAB may provide better sensitivity for low-expression samples

• Amplification methods: Consider tyramide signal amplification for detecting low abundance targets

• Counterstaining: Hematoxylin counterstaining helps visualize tissue architecture but may obscure weak nuclear staining

For optimal results with U2AF1L4 IHC, researchers should conduct preliminary optimization experiments comparing different fixation methods, antigen retrieval protocols, and antibody dilutions before proceeding with full experimental cohorts .

What quantification methods are appropriate for analyzing U2AF1L4 expression in tissue samples?

Accurate quantification of U2AF1L4 expression in tissue samples requires appropriate methodological approaches:

For immunohistochemistry (IHC) analysis:

• H-score method: Calculate H-score = Σ(i × Pi), where i = intensity (0-3) and Pi = percentage of positive cells at each intensity

• Allred scoring system: Combines proportion score (0-5) and intensity score (0-3) for a total score of 0-8

• Digital image analysis: Use software like ImageJ with appropriate plugins for automated nuclear staining quantification

• Cell-type specific quantification: Separately analyze nuclear staining intensity in different cell populations within heterogeneous tissues

For Western blot quantification:

• Densitometry analysis: Normalize U2AF1L4 band intensity to loading control (e.g., GAPDH, β-actin)

• Standard curve approach: Include recombinant U2AF1L4 protein at known concentrations for absolute quantification

• Replicate analysis: Perform at least three independent experiments for statistical reliability

Statistical analysis recommendations:

• For comparing expression between groups: non-parametric tests (Mann-Whitney U or Kruskal-Wallis) are often appropriate for IHC data

• For correlation with clinical parameters: Spearman's rank correlation for non-parametric data

• For survival analysis: Kaplan-Meier method with log-rank test, stratifying by U2AF1L4 expression levels

Reporting standards:

• Clearly describe scoring method and cutoff values used for categorization

• Report both raw data and normalized/transformed values

• Include representative images showing different staining intensities

• Provide information on inter-observer and intra-observer variability for manual scoring methods

These methodological approaches ensure rigorous quantification of U2AF1L4 expression, facilitating valid comparisons between experimental conditions or patient cohorts .

How should discrepancies between protein detection methods for U2AF1L4 be interpreted and resolved?

When different detection methods yield inconsistent results for U2AF1L4, a systematic approach to interpretation and resolution is necessary:

Common discrepancies and their causes:

• Western blot vs. IHC discrepancies: May reflect differences in epitope accessibility or protein conformation in fixed tissues versus denatured lysates

• Antibody-dependent variations: Different antibodies targeting distinct epitopes may yield varying results, especially if post-translational modifications affect epitope accessibility

• Species-specific differences: Antibodies with cross-reactivity to human, mouse, and rat may show variable sensitivity across species

Resolution framework:

• Methodological validation:

  • Verify antibody specificity using knockout/knockdown controls in each detection method

  • Confirm that protein extraction methods preserve U2AF1L4 integrity (particularly important for the relatively small 22 kDa protein)

  • Cross-validate with antibodies targeting different epitopes

• Biological interpretation:

  • Consider alternative splicing variants that might be differentially detected

  • Assess possible post-translational modifications affecting epitope recognition

  • Evaluate subcellular localization patterns as nuclear/cytoplasmic distribution may vary

• Technical reconciliation approach:

  • Use orthogonal methods (e.g., mass spectrometry) for independent verification

  • Correlate protein detection with mRNA expression (RT-qPCR or RNA-seq)

  • Implement proximity ligation assays to verify protein interactions in situ

Documentation and reporting recommendations:

• Clearly acknowledge discrepancies in research reports

• Present data from multiple detection methods rather than selecting only concordant results

• Discuss biological implications of discrepant findings rather than dismissing them

By systematically addressing discrepancies between different detection methods, researchers can gain deeper insights into U2AF1L4 biology and avoid misinterpretation of experimental results .

What are best practices for presenting U2AF1L4 antibody data in scientific publications?

When presenting U2AF1L4 antibody data in scientific publications, adherence to rigorous standards enhances reproducibility and credibility:

Essential reporting elements:

• Antibody details: Catalog number, vendor, clone (for monoclonal), host species, and lot number

• Validation evidence: Include knockout/knockdown controls or other specificity validation data

• Methodology specifications: Complete protocol details including blocking agents, antibody dilutions, incubation times/temperatures, and detection systems

Figure preparation guidelines:

• Western blot images: Show full blots with molecular weight markers; indicate U2AF1L4's expected 22 kDa band position

• IHC/ICC images: Include scale bars, magnification information, and examples of different staining intensities

• Controls: Present negative and positive control images alongside experimental samples

• Quantification: Include graphical representation of quantitative analyses with appropriate statistical tests

Technical transparency checklist:

• Disclose image acquisition parameters (exposure times, gain settings)

• Describe any image processing performed (contrast adjustment, etc.)

• For fluorescence images, specify filter sets and spectral unmixing methods if used

• For multiplexed detection, demonstrate specificity of each antibody individually

Reproducibility considerations:

• Indicate number of experimental replicates

• Report both technical and biological variability

• Address batch effects if experiments were conducted across multiple sessions

• Provide detailed methods to enable reproduction by other laboratories

Following these best practices not only improves publication quality but also contributes to the broader scientific community's ability to build upon your findings reliably. The transparency in reporting antibody-based experiments is particularly important given the variability in antibody performance across different laboratories and applications .

What emerging technologies might enhance U2AF1L4 antibody-based research in the future?

The field of U2AF1L4 antibody research stands to benefit from several emerging technologies that promise to enhance detection specificity, sensitivity, and biological insight:

Advanced antibody engineering approaches:

• Recombinant antibody fragments (Fab, scFv) with improved tissue penetration and reduced background

• Site-specific conjugation technologies for more consistent antibody labeling

• Nanobodies derived from camelid antibodies for accessing restricted epitopes in native conformation

High-resolution imaging technologies:

• Expansion microscopy to physically enlarge specimens for improved visualization of nuclear splicing compartments

• Lattice light-sheet microscopy for dynamic imaging of U2AF1L4 during splicing events

• Super-resolution techniques (STORM, PALM) for nanoscale localization within nuclear speckles

Single-cell and spatial technologies:

• Single-cell proteomics to quantify U2AF1L4 expression and modification states in individual cells

• Spatial transcriptomics combined with in situ protein detection to correlate U2AF1L4 localization with splicing activity

• Mass cytometry (CyTOF) with metal-conjugated antibodies for highly multiplexed detection in heterogeneous samples

Integrative approaches:

• CRISPR-based tagging of endogenous U2AF1L4 to eliminate antibody specificity concerns

• Proximity labeling techniques (BioID, APEX) to map the dynamic interactome of U2AF1L4

• Live-cell analysis using split fluorescent protein complementation to visualize splicing complex assembly

These technological advances will likely enable more precise characterization of U2AF1L4's dynamic roles in splicing regulation and may reveal previously unrecognized functions in normal physiology and disease states. Researchers should monitor developments in these areas as they may substantially enhance the capabilities of U2AF1L4-focused investigations in the coming years .

How can researchers ensure optimal reproducibility when working with U2AF1L4 antibodies across different research groups?

Ensuring reproducibility in U2AF1L4 antibody-based research across different laboratories requires systematic approaches to standardization and validation:

Antibody validation and selection framework:

• Implement multi-tiered validation using genetic models (knockouts/knockdowns), orthogonal detection methods, and cross-laboratory testing

• Establish a consensus on recommended antibody clones for specific applications based on validation data

• Consider creating centralized repositories of validation data for commercially available U2AF1L4 antibodies

Protocol standardization strategies:

• Develop detailed standard operating procedures (SOPs) with specific parameters for each application

• Include quantitative quality control metrics to assess staining quality objectively

• Establish positive control cell lines or tissues with well-characterized U2AF1L4 expression

Reference materials and calibration standards:

• Create stable reference cell lines with defined U2AF1L4 expression levels

• Develop recombinant protein standards for absolute quantification

• Establish digital reference images for IHC/ICC scoring calibration

Collaborative practices:

• Implement antibody validation ring trials across multiple laboratories

• Share raw data and detailed methodologies through repositories

• Adopt common reporting formats using the minimum information about antibody experiments guidelines

Technical considerations table: